SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CRLS - Chrysalis : Any followers ? Any comments ?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Lokness who wrote (30)11/13/1997 6:22:00 PM
From: BulbaMan  Read Replies (1) of 51
 
Unlike GZTC, CRLS is not really a pure play on transgenics. And I imagine the stock price of CRLS will be driven by the performance of its contract research business. Since I think there'll be increasing amounts of money spent on research by biotechs and pharmaceuticals, I expect CRLS's revenues and earnings (and stock price) to grow nicely.
In my mind, CRLS's transgenics-related patents are an extra bonus for shareholders. CRLS is a very small company. And, assuming sales of transgenic animals/plants really begin to grow, my impression is that CRLS's royalties could become quite significant for their bottom line. I doubt anyone can predict the extent of such royalties, but given CRLS's super-cheap stock price it seems you're getting the transgenics bet for free.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News